At the time of writing, NovoCure Ltd [NVCR] stock is trading at $17.65, down -2.49%. An important factor to consider is whether the stock is rising or falling in short-term value. The NVCR shares have gain 16.27% over the last week, with a monthly amount glided 20.40%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
NovoCure Ltd [NASDAQ: NVCR] stock has seen the most recent analyst activity on October 16, 2024, when H.C. Wainwright upgraded its rating to a Buy and also boosted its price target to $30 from $24. On August 28, 2023, downgrade downgraded it’s rating to Neutral and revised its price target to $25 on the stock. Piper Sandler upgraded its rating to a Overweight but stick to its price target of $45 on August 08, 2023. SVB Securities initiated its recommendation with a Outperform and recommended $51 as its price target on August 04, 2023. Evercore ISI upgraded its rating to In-line for this stock on July 31, 2023, but kept the price target unchanged to $33. In a note dated June 07, 2023, Wedbush upgraded an Neutral rating on this stock and revised its target price from $53 to $46.
For the past year, the stock price of NovoCure Ltd fluctuated between $10.87 and $24.74. Currently, Wall Street analysts expect the stock to reach $68.92 within the next 12 months. NovoCure Ltd [NASDAQ: NVCR] shares were valued at $17.65 at the most recent close of the market. An investor can expect a potential return of 290.48% based on the average NVCR price forecast.
Analyzing the NVCR fundamentals
According to NovoCure Ltd [NASDAQ:NVCR], the company’s sales were 577.74M for trailing twelve months, which represents an 21.81% jump. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at -0.28%, Pretax Profit Margin comes in at -0.2%, and Net Profit Margin reading is -0.26%. To continue investigating profitability, this company’s Return on Assets is posted at -0.12, Equity is -0.41 and Total Capital is -0.33. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.81.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.27 points at the first support level, and at 16.88 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.07, and for the 2nd resistance point, it is at 18.48.
Ratios To Look Out For
It is important to note that NovoCure Ltd [NASDAQ:NVCR] has a current ratio of 1.49. On the other hand, the Quick Ratio is 1.44, and the Cash Ratio is 0.25. Considering the valuation of this stock, the price to sales ratio is 3.31, the price to book ratio is 5.29.
Transactions by insiders
Recent insider trading involved Paravasthu Mukund, Chief Operating Officer, that happened on Nov 02 ’24 when 44.0 shares were sold. Chief Human Resources Officer, Puri Michal Nath completed a deal on Oct 31 ’24 to sell 810.0 shares. Meanwhile, EVP, Pres., Novocure Oncology Leonard Frank X sold 598.0 shares on Nov 01 ’24.
